Dr. Marcus Chen had been teaching at Columbia for twenty-two years, and the thing that distinguished him from other biostatisticians of comparable credential was his refusal to speak to juries the way biostatisticians usually spoke to juries.
Most expert witnesses in his field defaulted to precision. Chen defaulted to comprehension. He'd made the decision early in his expert career that winning the technical argument was less important than being understood, because a technically perfect argument that the jury couldn't follow was no argument at all.
He took the stand on day eleven of the trial, and the first thing he did was establish a metaphor.
"Before I describe what happened with Meridian's clinical trial data," he said, "I want to explain something about statistics using a comparison everyone here has encountered at some point. Either personally or in the news."
He looked at the jury.
"Bank fraud. Specifically: how a fraudulent bank manipulates its official books while knowing the real numbers exist somewhere else."
He spent five minutes on the bank fraud analogy. How a fraudulent bank maintains two sets of records: the official reports that auditors and regulators see, cleaned and optimized, showing healthy financial ratios. And the actual records, buried in backup systems, showing the real losses.
"The losses are real," Chen said. "The money is genuinely gone. The books look clean only because someone modified the accounting software to stop reporting the losses in the official category. Change one parameter in the software — reclassify the losses as 'asset transfers' rather than 'losses' — and the official books balance perfectly while the real situation is catastrophic."
He paused.
"Meridian did the same thing. Not with money. With patient safety data."
[ Win Rate Calculator: Jury comprehension assessment. Bank fraud analogy: high clarity — 11 of 12 jurors showing processing engagement. Analogy landing as intended. ]
The technical presentation came after the analogy.
Chen built it in three layers.
First layer: the unmodified backup data. From Meridian's archive, produced through discovery. A complete record of every cardiac adverse event observed during the Phase III trial, classified according to the original CDAT threshold parameters. Chen displayed the distribution chart.
Cardiac events at severity level 2 or above: 4.7% of trial participants. That percentage was represented by a clear bar on the chart. Not abstract. Visible.
"This is the real data," Chen said. "This is what the clinical trial actually found."
Second layer: the modified submitted data. The FDA application. The same chart, drawn from the numbers Meridian submitted.
Cardiac events at severity level 2 or above: 0%.
Zero. A flat line where the bar had been.
He let the jury look at the two charts side by side.
"Zero," he said, "is a number that requires explanation in any clinical trial. Adverse events of all kinds occur in trial populations at measurable rates. Zero adverse events of a specific type — zero of a type that appeared at 4.7% just months earlier — is not a finding. It is a signal that something has changed in how the events are being counted."
The jury was very still.
"The modification of the CDAT threshold parameter on March 14th, 2011, explains the difference between the two charts. Before the modification: 4.7%. After the modification: 0%. The events didn't disappear from the patients. They disappeared from the count."
Third layer: Chen's own statistical forensic analysis — the verification that the archive data and the submitted data were the only two versions of the data in Meridian's system, that the backup had been verified as authentic through hash comparison of the file metadata, and that the chain of custody for the archive production was documented and intact.
He was precise, methodical, and entirely clear.
The retired statistician in the jury box had been leaning forward since the second chart appeared.
The cross-examination from Eleanor Marsh was the best work she'd done in the trial.
She started with the backup file itself.
"Dr. Chen, you've testified that the archive backup file is authentic. What steps did you take to verify its authenticity?"
Chen walked through the verification: hash comparison showing file integrity, metadata consistent with original creation date of 2011, independent verification by Cahill's SEC forensic team. Thorough.
"And if the file had been corrupted during storage — not maliciously, but through routine data degradation — would the hash comparison necessarily detect that?"
"It would, yes. A corrupted file shows an altered hash."
"All types of corruption? Including partial data degradation?"
A brief pause. "Partial byte-level degradation can sometimes produce a file that passes hash verification but contains data errors."
Marsh turned to her table and retrieved Meridian's responsive expert report.
Meridian's own biostatistician took the stand in the afternoon session and testified for ninety minutes about data integrity challenges in long-term pharmaceutical archive systems. The core argument: the backup file, stored for years in a legacy system, might contain classification data that was corrupted — not maliciously modified but simply degraded through time and storage error. The data discrepancy between the archive and the submission might be the result of data corruption rather than deliberate manipulation.
It was a technically credible argument.
I watched two jurors who had been solidly plaintiff-favorable through Dr. Rowe's testimony shift in their seats.
The retired statistician looked skeptical. The engineers looked uncertain.
I wrote three words on my legal pad: Pattern vs. random.
Redirect examination.
"Dr. Chen," I said. "Counsel raised the possibility that the backup file's data discrepancy could be the result of corruption rather than modification. I want to ask you about data corruption. When digital files become corrupted through storage degradation, what does that look like statistically?"
"Corrupted data tends to produce random errors distributed across the affected fields," Chen said. "A corrupted database shows errors scattered throughout the data — wrong values appearing in unpredictable locations, missing records distributed without pattern."
"And when you examined the archive backup, what was the distribution of discrepancies between the archive and the submitted data?"
"The discrepancies were not random." He was completely level. "The archive and the submitted data were identical in every field — patient demographics, dosing information, symptom records, all other adverse event categories, all laboratory values — except one. The classification field for cardiac events at severity level 2."
"One field."
"One field. Out of over four thousand data fields in the trial dataset."
"And that one field is the field that was modified by the March 14th CDAT parameter change."
"Correct. The discrepancy is targeted, specific, and located precisely in the field affected by the software modification. That pattern is inconsistent with random storage corruption. Storage corruption doesn't know which field to corrupt."
I let that sentence stand.
The retired statistician was nodding. Small, controlled nods, the nods of someone confirming a hypothesis.
"One more question, Dr. Chen. Opposing counsel suggested that the parameter change might have been a routine software maintenance update. In your professional experience reviewing pharmaceutical clinical trial systems, what does routine software maintenance typically modify?"
"Routine maintenance addresses software performance — processing speed, memory allocation, compatibility updates. It does not modify clinical classification thresholds. Clinical classification thresholds are trial parameters, not software parameters. Changing them after data collection has begun alters the meaning of the data already collected."
"And in thirty years of pharmaceutical statistics work, have you seen a clinical classification threshold changed six days before an FDA application filing?"
A pause.
"No," he said. "I have not."
I sat down.
[ Win Rate Calculator: Chen testimony — redirect impact. Uncertainty recovery: estimated 80% of moved jurors returned to prior lean. Corruption argument effectively neutralized. Case probability: 64%. ]
Sixty-four percent. The highest since jury selection.
That evening I called Dr. Rowe.
"How are you holding up?" I said.
"Watching Dr. Chen today." She was quiet for a moment. "I keep thinking about all the people who were told this drug was safe."
"Keep thinking that," I said. "It's why we're here."
After I hung up, I sat with the trial notes.
Marsh still had her strongest witness coming — the Meridian CMO, who had been subpoenaed and would testify under immunity, and whose account of the March 14th parameter change had been carefully calibrated to withstand cross-examination. I'd seen the pre-trial deposition. It had not gone as well for him as his attorneys had hoped, but it had been better than I'd wanted.
He had an explanation for the six-day window.
It wasn't a good explanation. But it was an explanation, and juries sometimes found mediocre explanations sufficient.
I looked at the trial notes.
The case was at 64%.
The CMO testimony was the thing standing between 64% and the verdict.
I needed to destroy the explanation.
Not metaphorically. Specifically, precisely, and in front of twelve people who would understand exactly why the destruction was complete.
I opened the CMO's deposition transcript and started reading.
He'd made three claims about the parameter change. All three were technically defensible in isolation.
What they weren't was internally consistent.
The first claim contradicted the third when you read them in sequence against the version history timeline.
I wrote the inconsistency on a fresh page.
Argument Crusher was already running.
[ Argument Crusher: CMO deposition — contradiction analysis. Claim 1 (scientific review process) vs. Claim 3 (urgency of timeline) creates irreconcilable conflict with FDA submission timeline. Optimal cross-examination sequence: establish Claim 1 in detail, establish Claim 3 in detail, present the timeline that makes them mutually exclusive. ]
The cross-examination of the CMO was three weeks away.
I had three weeks to make the contradiction inescapable.
I kept reading.
A LOT More chapters reign FREE upon unwrittenrealm.com.
• Normal | $8 — 15 chapters ahead
• Advanced | $11 — 20 chapters ahead
• Overlord | $19 — 25 chapters ahead, plus request a refinement (plot, character, system) on any of my novels
patreon.com/TheFinex5
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰
― DECREE ―
More chapters reign FREE upon unwrittenrealm.com.
The throne acknowledges.
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰